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Advances in asthma management, particularly the introduction 
of controller medication of which inhaled corticosteroids are 
the most important, has resulted in a steady decline in asthma 
mortality in most countries.1,2 This is usually accompanied 
by a decline in episodes of near-fatal asthma attacks and 
hospitalisations, and a reduction in other indicators of asthma 
morbidity.1  These gains have led to a shift in thinking on 
the management of asthma, away from simply preventing 
death and hospitalisations, toward achieving and maintaining 
sustained control of all clinical features. This includes absence 
of daytime and night-time symptoms, no limitation of activities, 
no rescue β2-agonist use and normal lung function.3 
Recent research has confirmed that this goal is achievable 
in a large proportion of patients with asthma of all severities,3 
and new strategies have been devised to maintain these gains 
using the lowest effective treatment doses.4-7  Cost-benefit 
analyses have confirmed the efficacy of this approach in that a 
large proportion of asthma costs result from unscheduled visits 
and use of health care resources, such that it has recently been 
suggested that we cannot ‘afford to not control asthma’, even 
when initial maintenance therapy appears to be more costly.8
The so-called ‘control-driven’ approach to asthma 
management forms the theme of latest versions of international 
guidelines including the 2006 revision of the Global Initiative 
for Asthma (GINA).9,10 This approach sets as the goal of 
treatment, complete control of the clinical features of asthma. 
Both initial treatment and subsequent adjustments to treatment 
are directed towards achieving this goal. Following an 
approach identical in concept to that for other chronic diseases 
like diabetes and hypertension, the new asthma management 
and prevention programme recommends an initial assessment 
of asthma control, treatment to achieve control and monitoring 
and adjustment of therapy to maintain control.
This approach differs from that in previous guidelines in 
that the latter tended to define degrees of asthma severity 
and to recommend treatment accordingly. The aim was to 
prevent serious morbidity and mortality rather than to offer 
a normal quality of life and activities free from the limitations 
of asthma. Treatment was therefore selected according to an 
arbitrary definition of severity, with the aim of improving 
rather than controlling disease, and because the consequences 
of uncontrolled asthma have not been perceived to be as 
important or dramatic as those of uncontrolled diabetes or 
hypertension, health care professionals and even patients were 
accepting of persistent limitation.  This approach is no longer 
considered acceptable. 
Assessment of control has been hampered by lack of a 
simple means of monitoring asthma. There is a need for 
regular, frequent assessments of control, using a simple 
validated instrument because health care professionals often 
underestimate the symptoms and limitations experienced 
by their patients, and patients themselves or caregivers of 
asthmatic children are often unaware of how their lives are 
limited and activities curtailed by their asthma.  Objective 
measures of asthma control equivalent to a blood glucose or 
glycosylated haemoglobin in diabetes are needed.  A number of 
asthma control measures have now been devised and validated 
and are being promoted both for self-assessment by patients 
with asthma, and for use by their caregivers and/or doctors.9 
Assessment of control requires a composite measurement of 
clinical indicators. Such asthma control measures may also be 
useful as a guide to adjusting therapy to maintain maximal 
control with minimum doses of medicines. These include step-
down routines, as once asthma is controlled, reductions may be 
safely carried out in the majority of patients.5,9
Recently, a novel approach to making these adjustments 
to treatment has been proposed. Termed the single inhaler 
for maintenance and relief therapy (SMART) approach, 
this method only applies to those patients using a single 
combination inhaler containing the inhaled steroid budesonide 
and long-acting β2-agonist, formoterol, in a fixed combination.6,7 
With this approach, patients take a regular daily dose of 
the combination as preventer (usually twice daily), but are 
able to take an additional dose or more at the first symptom 
of deterioration. This approach is possible as formoterol is 
a long-acting bronchodilator with a rapid onset of action. 
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early intervention in this way may prevent development of 
exacerbations and permit maintenance of control at remarkably 
low levels of controller treatment. Further studies of children 
and preschool children are needed as there is no separate 
published paediatric data on this strategy, and long-acting β2-
agonists are not approved for use in preschool children.
How do these promising developments relate to South 
Africa?  Firstly, current epidemiological data suggest that 
asthma is very common and increasing in prevalence. In recent 
surveys, utilising international methodology that permits 
comparisons with other countries (the International Study of 
Asthma and Allergies in Childhood (ISAAC) surveys)11 the 
12-month prevalence of asthma among 13 - 14-year-old South 
African adolescents was 20.3% higher than either the African 
(15.4%) or the global (13.7%) average. Moreover, an increase in 
asthma prevalence from 16.1% to 20.3% occurred over a 7-year 
period.11-13 More alarming, however, was that in surveys of 
asthma mortality, South Africa ranked 4th or 5th highest in the 
world, whether expressed as deaths as a percentage of the total 
population or of the asthma population.13 Further analysis of 
the Cape Town ISAAC phase 1 data demonstrated that while 
asthma was more prevalent in affluent households, the burden 
of morbidity and mortality was greatest in households with low 
socio-economic status.14  Although many factors operating in 
impoverished communities contribute to the suboptimal care 
of children with chronic diseases like asthma, access to and the 
availability of controller medication remains one of the most 
important preventable factors.15
Although most South African asthma data relate to 
the Western Cape, some studies provide indicators of the 
situation in other parts of the country. Dating back to earliest 
observations by Wesley et al. on the differences of asthma 
admissions among black, Indian and white children in Durban, 
the rate of asthma events has been known to be lower among 
black children.16 However, in 1979, van Niekerk and colleagues 
demonstrated that this lower rate applied especially to black 
children from rural areas,17 their study showed that the 
prevalence of exercise-induced broncho-constriction in Xhosa 
children in Cape Town (3.17%) was 22 times higher than that 
of age-matched rural children in the Transkei (0.14%).  Recent 
prevalence studies of asthma among school children in the 
harbour basin of Durban and in Thokoza, Gauteng, using 
different methodologies, have confirmed high levels of asthma, 
at least equal to those in Cape Town.18,19 Two additional studies 
of Xhosa children, similar to the original study by van Niekerk 
et al. have reported prevalences of 34% and 14.5% in one 
study, and 17% and 8.6% in urban and rural black children, 
respectively.20,21 Thus there is a rising asthma prevalence in both 
urban and rural children, with a reduction in the urban-rural 
gradient.
Under-recognition and under-treatment of a large proportion 
of both children and adults with asthma is a consistent feature 
in local and international studies of the global burden of 
asthma. Large-scale surveys performed on several continents 
have confirmed unnecessary morbidity in the form of limitation 
of activities, absenteeism from work and school, nocturnal 
wakening and hospitalisations resulting from inadequate 
recognition and treatment of asthma.22 In South Africa, even 
in patients with access to medication, the persistence of 
symptoms is unacceptably high. In a sample of 710 asthma 
patients surveyed in 1999 by Green and Rens,23 although 
most were on inhaled corticosteroids, 46% described daily 
limitation of activity and an alarming 37% reported night-
waking due to asthma on 4 or more occasions per week.  Only 
35% had not missed work or school in the preceding year and 
16% reported a hospital admission during the previous year. 
There is an urgent requirement for increasing awareness of 
the diagnosis of asthma and of the use of effective controller 
regimens with long-term monitoring and follow-up.  Although 
inhaled corticosteroids form part of the essential drug list 
and are available in most community health centres, under-
prescribing, incorrect use or an erratic drug supply may be 
causes of preventable asthma-related morbidity and mortality. 
Furthermore there is a need to address cultural and language 
differences in defining asthma symptoms and a need to 
develop appropriate control measures and patient education for 
different patient populations.  
Management of asthma in South Africa therefore appears to 
be suboptimal. How should the situation be addressed? 
First must be the revision of the goals of asthma management 
toward controlling disease rather than simply avoiding 
hospitalisations or death.  Erratic or partial treatment 
and improved access to emergency facilities for asthma 
exacerbations may have a modest effect on mortality, but will 
have little or no effect on the medical and societal burden of 
asthma.  
What is required is a sustained co-ordinated emphasis on 
management of chronic respiratory diseases in which the 
diagnosis and management of asthma with effective controller 
drugs remains an important priority.  The importance of 
chronic respiratory disease has recently attracted renewed 
interest and was identified in May 2000 as an important health 
priority particularly in developing countries by the World 
Health Assembly of the World Health Organization.  This led 
to the creation and launch in March 2006 of the Global Alliance 
Against Respiratory Diseases (GARD).  Among the GARD 
priorities are to propose a step-wise and integrated programme 
of prevention and control of preventable chronic respiratory 
allergies, with a special focus on developing countries, with 
asthma as one of the priority diseases.  This development is 
timely in the light of the great strides that have been made 
in asthma management. For South Africa, the challenge is to 
ensure that asthma is not forgotten or eclipsed by the heavy 
burden of infectious respiratory diseases.  Priorities are the 
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need for surveys on the morbidity and mortality of asthma in 
all provinces among both adults and children, the revision of 
guidelines in the light of the international trends mentioned 
above, patient and health care provider education and 
improved access to and use of controller therapy. In the public 
sector, an approach with some promise is the use of integrated 
guidelines in primary care that increase awareness and simplify 
asthma management and the incorporation of guidelines for 
management of childhood wheezing into the South African 
adaptation of the Integrated Management of Childhood Illness 
approach.24 South Africa already has an infrastructure on which 
to build – existing guidelines for childhood and adult asthma, 
an essential drug list that includes inhaled corticosteroids, 
and a national asthma education programme. We have the 
tools to control asthma effectively – the challenge is to achieve 
widespread implementation and use of a control-driven 
strategy. 
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